Survival after transplantation in the m2a intermediate-risk group of leukemia is fair, with five-year survival ranging from 40% to 60%. Acute m2a leukemia intermediate-risk group, can be allogeneic hematopoietic stem cell transplantation treatment after the disease by induction therapy to achieve complete remission, five-year survival ranging from 40% to 60%. Drugs include cytarabine and Zoerythromycin. Leukemia can be divided into acute leukemia and chronic leukemia. m2 is a kind of acute myeloid leukemia, which is characterized by partial differentiation of primitive granulocytes, massive proliferation of leukemia cells in the bone marrow, inhibition of normal hematopoietic function of the bone marrow, and clinical symptoms such as anemia, infection, and infiltration of extramedullary organs, etc. m2 can be divided into two kinds of m2, one of which is m2a. Specific diagnosis and treatment should be carried out under the guidance of physicians.